Back to Search
Start Over
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.
- Source :
-
Clinical rheumatology [Clin Rheumatol] 2018 May; Vol. 37 (5), pp. 1417-1420. Date of Electronic Publication: 2018 Apr 02. - Publication Year :
- 2018
-
Abstract
- GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Drug Therapy, Combination
Female
Humans
Male
Methotrexate therapeutic use
Middle Aged
Prospective Studies
Remission Induction
Severity of Illness Index
Treatment Outcome
Young Adult
Antibodies, Monoclonal therapeutic use
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1434-9949
- Volume :
- 37
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 29611083
- Full Text :
- https://doi.org/10.1007/s10067-018-4074-6